Rhythm Pharma

Recordings now available: Rhythm-sponsored Hub sessions at ECE 2024

Session 1: Sunday 12 May - Rare hypothalamic melanocortin-4 receptor (MC4R) pathway diseases: hyperphagia and early-onset, severe obesity

KEY TOPICS:

Overview of MC4R pathway impairments leading to monogenic and syndromic disease
Hyperphagia as a cardinal symptom
Challenges in diagnosis and importance of genetic testing, with focus on Bardet-Biedl Syndrome (BBS)

Session 2: Monday 13 May - The role of precision medicine in managing rare MC4R pathway disease, from monogenic obesity to Bardet-Biedl syndrome

KEY TOPICS:

Burden of disease and quality of life
Clinical experience
Multidisciplinary care and the impact of precision medicine

Prof. Giovanni Ceccarini discusses the burden of living with a rare MC4R pathway disease and the impact on quality of life, as well as the importance of multi-disciplinary care and the impact of precision medicine

The role of precision medicine in managing rare MC4R pathway disease, from monogenic obesity to Bardet-Biedl syndrome

Prof Giovanni Ceccarini

Please login or signup to unlock the videos

Rhythm Pharmaceuticals is leveraging a IQVIA's Healthcare Professional Authentication solution to identify your eligibility to access this video content. If you already have an IQVIA account using it with other healthcare providers, please click 'Login' otherwise click 'Signup'.

Login Signup

Rare hypothalamic melanocortin-4 receptor (MC4R) pathway diseases: hyperphagia and early-onset, severe obesity

Dr Danilo Fintini